Newleos Therapeutics has appointed Rohan Palekar as chairman of its board of directors, bringing in an executive who most recently led 89bio from an emerging biotechnology company to its acquisition by Roche. The appointment comes as Newleos advances clinical-stage programmes targeting generalized anxiety disorder, social anxiety disorder and alcohol use disorder, shifting the company’s central challenge from assembling a promising portfolio to producing convincing human evidence.
Palekar’s arrival does not change the clinical status of Newleos’ investigational medicines, and it should not be interpreted as validation that any of its mechanisms will succeed. It does, however, strengthen the company’s strategic oversight at a point when trial design, capital allocation, regulatory planning and decisions about future financing or partnerships will begin to carry greater consequences.
Newleos launched in 2025 with an oversubscribed $93.5 million Series A financing led by Goldman Sachs Alternatives. Its investors also included Novo Holdings, Longwood Fund, DCVC Bio and Arkin Bio Capital. The company’s portfolio of oral small molecules was licensed from Roche and includes candidates targeting GABA-A gamma-1, vasopressin 1a, trace amine-associated receptor 1 and GABA-A alpha-5.
Why is Rohan Palekar’s experience at 89bio relevant to Newleos’ clinical-stage strategy?
Palekar’s most relevant qualification is not simply that he has run a biotechnology company. It is that he has managed several different stages of the biotechnology value chain, including company formation, clinical development, manufacturing scale-up, public-market financing and an eventual strategic transaction.
He became chief executive officer of 89bio in 2018 and helped advance pegozafermin from preclinical development into multiple Phase 3 studies for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia. Roche completed its acquisition of 89bio on October 30, 2025, paying $14.50 per share in cash and issuing contingent value rights that could provide up to an additional $6 per share if specified milestones are achieved.
That history matters because Newleos is likely to face several of the same organisational questions that confront most privately held clinical-stage companies. Management must decide how many programmes can be funded simultaneously, which clinical signals justify larger studies, when manufacturing and regulatory capabilities should be expanded, and whether the strongest route forward involves remaining independent, entering a partnership or eventually pursuing a transaction.
Palekar also brings commercial and operational experience from Avanir Pharmaceuticals, Medivation and Johnson & Johnson. At Avanir, he served as president and chief executive officer following the company’s acquisition by Otsuka Pharmaceutical. At Medivation, his responsibilities included commercial operations, medical affairs and chemistry, manufacturing and controls. This combination may be particularly useful if Newleos eventually needs to connect early clinical findings with a realistic development and commercial strategy.
The immediate task, however, is far earlier and less glamorous than launching a medicine or negotiating an exit. Newleos must demonstrate that its selective neuroscience mechanisms generate measurable, clinically relevant effects in appropriately controlled studies.
How will the new board chairman work alongside chief executive officer Timothy Noyes?
Newleos appointed Timothy Noyes president and chief executive officer in October 2025, replacing founding chief executive David Donabedian, who continued with the company in an advisory capacity. Noyes previously led Aerovate Therapeutics and Proteon Therapeutics, taking both businesses through public listings and overseeing clinical programmes that progressed into later-stage development.
The pairing of Noyes and Palekar gives Newleos two executives with experience navigating capital-intensive clinical programmes. Noyes is responsible for day-to-day leadership and operational execution, while Palekar’s board role should concentrate on governance, strategic prioritisation and management accountability.
That distinction will be important. Newleos has four named clinical or clinically tested assets, but it does not have unlimited capital. The company will need to resist the common biotechnology temptation to advance every theoretically attractive programme at the same speed. A broad pipeline can reduce dependence on a single asset, but it can also dilute management attention and shorten the runway if several expensive trials overlap.
The board’s most valuable contribution may therefore be disciplined selection. That means identifying which data packages would genuinely change the company’s valuation or strategic options, and which programmes should remain behind the lead assets until stronger evidence or additional financing becomes available.
Why will the SOAR Phase 2 study of NTX-1472 be Newleos’ clearest near-term test?
NTX-1472 is a selective, brain-penetrant antagonist of the vasopressin 1a receptor being investigated for social anxiety disorder. Newleos is evaluating the candidate in the SOAR Phase 2 study, a multicentre, randomized, double-blind and placebo-controlled trial.
The study is expected to enrol approximately 100 adults with social anxiety disorder. Participants receive NTX-1472 or placebo daily for eight weeks, with safety, tolerability and efficacy assessments conducted during a study period extending to approximately 14 weeks. ClinicalTrials.gov lists January 2027 as the estimated primary completion date.
Of Newleos’ active studies, SOAR may provide the most interpretable near-term evidence because it is a conventional Phase 2 comparison against placebo in a defined patient population. Unlike a healthy-volunteer pharmacology study or an experimental laboratory paradigm, it is designed to examine whether the candidate can improve symptoms in people diagnosed with the intended condition.
The challenge is that psychiatric trials are vulnerable to high placebo responses, variable symptom reporting and differences among study sites. A positive headline result will therefore not be enough by itself. The magnitude, consistency and timing of any benefit will matter, as will treatment discontinuations and the candidate’s effects on broader functioning.
Newleos describes NTX-1472 as a potential best-in-class programme, but that positioning remains a development hypothesis. The Phase 2 study must first establish whether selective V1a receptor antagonism produces a clinically meaningful benefit and whether the effect is sufficiently robust to support a larger confirmatory programme.
What must the NTX-1955 Phase 1b programme establish before generalized anxiety disorder development expands?
NTX-1955 is designed as a selective positive allosteric modulator of GABA-A receptors containing the gamma-1 subunit. Newleos’ scientific proposition is that targeting receptor populations enriched in anxiety-related brain circuits could retain anxiolytic activity while avoiding some of the sedation, cognitive effects and dependence risks associated with nonselective benzodiazepines.
The company is conducting two Phase 1b studies in the European Union and a third study in the United Kingdom. The United Kingdom trial is randomized, double-blind and placebo-controlled, with participants receiving one of two NTX-1955 dose levels or placebo once daily for two weeks. Its primary focus is safety and tolerability, while pharmacokinetic and exploratory quantitative electroencephalography measurements are intended to provide information about drug exposure and pharmacodynamic activity.
Data from the three studies are expected to guide dose selection and the design of a Phase 2 efficacy trial. That makes the programme an important test of whether Newleos can translate a receptor-selectivity argument into evidence that the drug is engaging the intended neural pathways at tolerable doses.
Preclinical findings cited by the company suggest anxiolytic activity without the same side-effect profile observed with conventional benzodiazepines. Those findings support continued investigation, but they cannot establish that the distinction will hold in patients. Sedation, cognitive performance, dose response, exposure and repeated-dose tolerability will require careful assessment as development progresses.
A commercially useful anxiety medicine would need more than statistical separation from placebo. It would need an onset and magnitude of benefit that matter to patients, along with tolerability capable of supporting sustained use. NTX-1955 remains several clinical steps away from answering those questions.
How does NTX-2001 broaden Newleos’ opportunity while adding another layer of development risk?
Newleos began a Phase 1b proof-of-concept study of NTX-2001 in alcohol use disorder in April 2026. The candidate is a partial agonist of trace amine-associated receptor 1, or TAAR1, and is intended to modulate dopamine signalling within neural circuits associated with reward and reinforcement.
The randomized, double-blind, placebo-controlled study is being conducted with Yale School of Medicine. Its primary endpoint measures alcohol consumption during an alcohol drinking paradigm, a controlled human laboratory model intended to simulate drinking behaviour. Secondary assessments include safety, tolerability and other clinical measurements.
NTX-2001 has previously been studied in healthy volunteers and people with schizophrenia or schizoaffective disorder, providing Newleos with an existing human exposure and safety dataset. The company reports that approximately 645 participants received either the candidate or placebo across eight earlier studies.
That history may reduce some early uncertainty concerning dosing and tolerability, but it does not demonstrate efficacy in alcohol use disorder. The Phase 1b alcohol drinking paradigm can provide an early signal of whether the mechanism influences consumption or craving under controlled conditions. It cannot by itself establish durable abstinence, reduced harmful drinking or improved real-world health outcomes.
A favourable signal could justify a larger outpatient study and potentially support development in other substance use disorders. An inconclusive result would force Newleos to decide whether the limitations arose from the molecule, the mechanism, the selected dose or the experimental model. Palekar’s experience in portfolio decision-making could become especially relevant when interpreting such ambiguous early-stage evidence.
Does the Roche connection make a future partnership more likely?
Newleos licensed its pipeline from Roche, while Palekar’s previous company was acquired by Roche. The overlap is strategically interesting, but there has been no disclosed indication that his appointment is connected to a new Roche transaction or that Roche plans to reacquire any Newleos programme.
The more practical benefit is that Palekar understands how both emerging biotechnology companies and large pharmaceutical groups assess development risk. That perspective may help Newleos build data packages capable of surviving the scrutiny of potential investors, partners and acquirers.
Large pharmaceutical companies generally do not pay premium valuations merely for novel mechanisms. They seek evidence that a candidate has a defensible dose, a reproducible clinical effect, manageable safety risks, scalable manufacturing and a regulatory path that can be translated into a commercially relevant label.
Newleos’ Roche-derived molecules entered the company with previous research and clinical work behind them, allowing development to begin further along than a conventional discovery-stage portfolio. Yet every new indication and trial still requires independent validation. The origin of the assets may improve their starting position, but it cannot eliminate biological or clinical risk.
What will determine whether the board appointment creates lasting value for Newleos?
Palekar’s appointment gives Newleos a chairman who has experienced the full arc of biotechnology development, including the difficult transition from early promise to expensive late-stage execution. That is a meaningful governance asset for a company running multiple human studies.
The measurable value of the appointment will nevertheless be determined by decisions rather than biography. Newleos must complete its studies efficiently, select doses on credible evidence, preserve sufficient financing flexibility and avoid expanding the pipeline faster than its data or capital can support.
The SOAR trial of NTX-1472 is positioned to provide the company’s clearest patient-level efficacy test. The NTX-1955 studies must establish a convincing pharmacological foundation for Phase 2 development, while NTX-2001 must show that a controlled drinking paradigm can generate an interpretable signal in alcohol use disorder.
A strong board can improve prioritisation, oversight and strategic preparation. It cannot manufacture a clinical effect. Palekar’s most important contribution will be helping Newleos recognise the difference between an encouraging signal worth financing and an attractive scientific narrative that has not yet earned further investment.
